New hope for Tough-to-Treat blood cancer
NCT ID NCT05502250
Summary
This study is testing whether a drug called tislelizumab, when combined with standard chemotherapy, works as well as the usual intensive treatment for Hodgkin lymphoma that has returned or didn't respond to first-line therapy. The trial involves 75 adults aged 18-70. The goal is to see if this approach can control the cancer and keep it from progressing, potentially offering an alternative to stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BE-Bruxelles-STLUC
Brussels, Belgium
-
DK-Aarhus N-AUH
Aarhus, Denmark
-
DK-Copenhagen-RIGSHOSPITALET
Copenhagen, Denmark
-
DK-Odense-OUH
Odense, Denmark
-
NL-Amersfoort-MEANDERMC
Amersfoort, Netherlands
-
NL-Amsterdam-AMC
Amsterdam, Netherlands
-
NL-Arnhem-RIJNSTATE
Arnhem, Netherlands
-
NL-Den Haag-HAGA
The Hague, Netherlands
-
NL-Eindhoven-MAXIMAMC
Eindhoven, Netherlands
-
NL-Goes-ADRZ
Goes, Netherlands
-
NL-Groningen-UMCG
Groningen, Netherlands
-
NL-Hoofddorp-SPAARNEGASTHUIS
Hoofddorp, Netherlands
-
NL-Leeuwarden-MCL
Leeuwarden, Netherlands
-
NL-Maastricht-MUMC
Maastricht, Netherlands
-
NL-Rotterdam-ERASMUSMC
Rotterdam, Netherlands
Conditions
Explore the condition pages connected to this study.